Loading…
BridgeBio Oncology Therapeutics, Inc. is projected to rise to $10.15 by 2027, a +25% move from its current price of $8.09. BBOT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $7.86 | $8.09 | $8.33 | 0.00% |
| Aug 3 | $7.76 | $8.09 | $8.43 | +0.01% |
| Aug 4 | $7.69 | $8.09 | $8.51 | +0.01% |
| Aug 5 | $7.63 | $8.09 | $8.58 | +0.01% |
| Aug 6 | $7.58 | $8.09 | $8.64 | +0.02% |
| Aug 7 | $7.54 | $8.09 | $8.69 | +0.02% |
| Aug 8 | $7.49 | $8.09 | $8.74 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.49 | $8.09 | $8.74 | +0.03% |
| Week 2 | $7.26 | $8.09 | $9.03 | +0.05% |
| Week 3 | $7.09 | $8.10 | $9.25 | +0.08% |
| Week 4 | $6.94 | $8.10 | $9.45 | +0.10% |
| Week 5 | $6.82 | $8.10 | $9.62 | +0.13% |
| Week 6 | $6.71 | $8.10 | $9.78 | +0.15% |
| Week 7 | $6.61 | $8.10 | $9.94 | +0.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company that develops small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
BBOT is a healthcare stock with a current price of $8.32 and a market capitalization of $666.49M. It is ranked 2827 by market cap. The latest price outlook shows a neutral near-term path in 2026 with an average price of $8.32 and 0% ROI.
The longer-term forecast paints a bullish trajectory into the late 2020s and beyond, with gradual price appreciation and sizable ROI by 2030 and beyond.
A major floor 19.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.5% below — buyers have tended to step in here.
The nearest ceiling, 12.4% above — a clean break opens room to run.
A major ceiling 22.2% above — clearing it would confirm fresh momentum.
Key BBOT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BBOT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.43 | Sell | $8.38 | Sell |
| MA 10 | $8.57 | Sell | $8.47 | Sell |
| MA 20 | $8.57 | Sell | $8.44 | Sell |
| MA 50 | $8.21 | Sell | $8.40 | Sell |
| MA 100 | $8.51 | Sell | $8.78 | Sell |
| MA 200 | $10.13 | Sell | $9.48 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.23 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -143.17 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -3.80 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | 0.23 | Buy |
| Ultimate (7,14,28) | 33.28 | Neutral |
| Momentum (10) | -0.47 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 8.23 | Sell |
| ADX (14) | 11.06 | Neutral |
| ATR (14) | 0.25 | Info |
The 30-day technical picture is described as BULLISH. The RSI(14) is 50, and the stock trades around key moving averages with the SMA50 at $8.13 and the SMA200 at $10.38. Near-term support sits at $7.12 and resistance at $9.09, providing a defined trading range. The 30-day range spans from $6.64 to $10.43, offering a measured window for potential moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.12 | $8.09 | $10.96 | 0% | Neutral | |
| $8.05 | $10.15 | $13.56 | +25% | Bullish | |
| $9.97 | $12.96 | $18.02 | +60% | Bullish | |
| $10.16 | $13.55 | $19.43 | +68% | Bullish | |
| $10.02 | $13.65 | $20.09 | +69% | Bullish | |
| $10.72 | $14.91 | $22.45 | +84% | Bullish | |
| $10.77 | $15.27 | $23.44 | +89% | Bullish | |
| $11.49 | $16.58 | $25.93 | +105% | Bullish | |
| $13.49 | $19.79 | $31.47 | +145% | Bullish | |
| $15.23 | $22.71 | $36.68 | +181% | Bullish | |
| $17.79 | $28.54 | $49.17 | +253% | Bullish | |
| $31.93 | $58.12 | $110.01 | +618% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.12 | $8.09 | $10.10 | +0.00% |
| September 2026 | $7.01 | $8.31 | $10.14 | +2.67% |
| October 2026 | $6.80 | $8.12 | $10.02 | -2.28% |
| November 2026 | $6.99 | $8.39 | $10.46 | +3.42% |
| December 2026 | $7.22 | $8.72 | $10.96 | +3.92% |
Click any year to see its month-by-month BBOT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BBOT to range from $7.12 to $10.96 through 2026. The $8.09 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BBOT price prediction for 2027 points to an average of $10.15 (low $8.05, high $13.56) — a potential gain of +25% on today's $8.09. Buyers look set to stay in control over this stretch.
In 2028, BBOT is projected to trade between $9.97 and $18.02, averaging $12.96 — a potential gain of +60% from today's $8.09. That is up +28% on the projected 2027 average. Momentum favours further upside here.
BridgeBio Oncology Therapeutics, Inc.'s 2029 outlook centres on $13.55, within a $10.16 to $19.43 range. That is up +5% on the projected 2028 average. That marks a +68% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, BBOT could reach as high as $20.09, with a base case around $13.65 and support toward $10.02 — roughly +69% from $8.09. Momentum favours further upside here.
Expect BBOT to range from $10.72 to $22.45 through 2031. The $14.91 average target implies a +84% move from current prices. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BBOT price prediction for 2032 points to an average of $15.27 (low $10.77, high $23.44) — a potential gain of +89% on today's $8.09. Momentum favours further upside here.
In 2033, BBOT is projected to trade between $11.49 and $25.93, averaging $16.58 — a potential gain of +105% from today's $8.09. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
BridgeBio Oncology Therapeutics, Inc.'s 2034 outlook centres on $19.79, within a $13.49 to $31.47 range. That is up +19% on the projected 2033 average. That marks a +145% change versus current levels. Momentum favours further upside here.
By 2035, BBOT could reach as high as $36.68, with a base case around $22.71 and support toward $15.23 — roughly +181% from $8.09. Buyers look set to stay in control over this stretch.
Expect BBOT to range from $17.79 to $49.17 through 2040. The $28.54 average target implies a +253% move from current prices. That is up +26% on the projected 2035 average. Momentum favours further upside here.
The BBOT price prediction for 2050 points to an average of $58.12 (low $31.93, high $110.01) — a potential gain of +618% on today's $8.09. Buyers look set to stay in control over this stretch.
Investing $1,000 in BBOT today (≈ 123.609394 BBOT) could be worth
$7,183.89
+$6,183.89 (+618%) by 2050 · US Dollar
Based on the average projected BBOT price of $58.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BBOTwould be worth at today's price.
$1,000 invested in BBOT on Jul 31, 2025 (≈ 94.339619 BBOT) would be worth
$763.21
-$236.79 (-23.7%) today · 0.76× · US Dollar
Based on a BBOT entry price of $10.6 vs. today's $8.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.82 | $917.23 | -8.3% |
| 1 month ago | $7.8 | $1,037.18 | +3.7% |
| 3 months ago | $8.39 | $964.24 | -3.6% |
| 6 months ago | $12.03 | $672.49 | -32.8% |
| 1 year ago | $10.6 | $763.21 | -23.7% |
| All time (2.5y) ago | $10.19 | $793.92 | -20.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BBOT forecast.
Our base-case forecast reaches $16.00 around 2033.
Implied market cap at $16.00: $1.28B
The multi-year forecast shows a bullish trajectory across the horizon. In 2026 the avg price is $8.32 with a min of $7.12 and a max of $11.43 and 0% ROI, sentiment Neutral. By 2027 the avg rises to $10.45 with a min of $8.12 and a max of $14.34 and a 25.6% ROI, sentiment Bullish.
The path continues higher through 2028 with an avg of $13.74 and a 65.2% ROI, then 2029 at $13.63 with 63.8% ROI, and 2030 at $13.64 with 63.9% ROI. Subsequent years show continued gains: 2031 avg $15.39 (84.9% ROI), 2032 avg $14.53 (74.6% ROI), 2033 avg $15.82 (90.1% ROI), 2034 avg $20.07 (141.3% ROI), 2035 avg $22.10 (165.6% ROI). The forecast projects 2040 with avg $27.53 and 230.9% ROI, and 2050 with avg $54.19 and 551.4% ROI.
These figures reflect a bullish longer-term outlook but are estimates, not guarantees, and investors should consider the inherent uncertainty in such projections.
Tap a question to reveal the answer.
The 2027 forecast shows an average price of $10.45, with a range from $8.12 to $14.34 and a 25.6% ROI. The sentiment is bullish.
The forecast indicates a bullish long-term trajectory with rising averages from 2027 onward (e.g., 2027 avg $10.45, 2028 avg $13.74, 2030 avg $13.64, 2050 avg $54.19), but 2026 shows neutral sentiment with 0% ROI. These are estimates, not guarantees.
Yes, according to the forecast, the 2040 max is $50.26 and the 2050 max is $109.77, with the 2050 avg at $54.19 and a 551.4% ROI.
The current price is $8.32 and the market capitalization is $666.49M.
The 30-day picture is bullish with RSI(14) at 50, SMA50 at $8.13, SMA200 at $10.38, support at $7.12, resistance at $9.09, and a 30-day range of $6.64 to $10.43.
BridgeBio Oncology Therapeutics, Inc. Community Discussion
0Share your BridgeBio Oncology Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.